Vitamin D-Induced Hypercalcemia in Experimental Renal Failure

Nephron ◽  
1977 ◽  
Vol 18 (1) ◽  
pp. 26-34 ◽  
Author(s):  
Steven E. Weisbrode ◽  
Charles C. Capen
Keyword(s):  
Vitamin D ◽  
Renal Failure ◽  
Experimental Renal Failure

scholarly journals Effect of vitamin D metabolites on calcitriol metabolism in experimental renal failure

1989 ◽  
Vol 36 (2) ◽  
pp. 234-239 ◽  
Author(s):  
Sanjeev Patel ◽  
Robert U. Simpson ◽  
Chen H. Hsu
Keyword(s):  
Vitamin D ◽  
Renal Failure ◽  
Vitamin D Metabolites ◽  
Experimental Renal Failure

THE EFFECT OF EXPERIMENTAL RENAL FAILURE ON TOLFENAMIC ACID DISPOSITION IN THE DOG

1997 ◽  
Vol 18 (1) ◽  
pp. 79-91 ◽  
Author(s):  
HERVÉ P. LEFEBVRE ◽  
VALÉRIE LAROUTE ◽  
MICHEL ALVINERIE ◽  
MARC SCHNEIDER ◽  
PATRICK VINCLAIR ◽  
...  
Keyword(s):  
Renal Failure ◽  
Tolfenamic Acid ◽  
Experimental Renal Failure

scholarly journals Impairment of cardiac function and energetics in experimental renal failure.

1993 ◽  
Vol 92 (6) ◽  
pp. 2934-2940 ◽  
Author(s):  
A E Raine ◽  
A M Seymour ◽  
A F Roberts ◽  
G K Radda ◽  
J G Ledingham
Keyword(s):  
Renal Failure ◽  
Cardiac Function ◽  
Experimental Renal Failure

Lymphocytopenia in Acute Experimental Renal Failure

1974 ◽  
Vol 47 (1) ◽  
pp. 80-86 ◽  
Author(s):  
Raymond G. Slavin ◽  
Neil I. Gallagher
Keyword(s):  
Renal Failure ◽  
Experimental Renal Failure

scholarly journals Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure

2010 ◽  
Vol 26 (3) ◽  
pp. 832-838 ◽  
Author(s):  
S. Bernardi ◽  
R. Candido ◽  
B. Toffoli ◽  
R. Carretta ◽  
B. Fabris
Keyword(s):  
Renal Failure ◽  
At1 Receptor ◽  
Receptor Blockade ◽  
Accelerated Atherosclerosis ◽  
Experimental Renal Failure

scholarly journals Dynamic changes in calcium and phosphate plasma concentrations in the patients on peritoneal dialysis

2006 ◽  
Vol 63 (1) ◽  
pp. 27-30
Author(s):  
Natasa Jovanovic ◽  
Mirjana Lausevic ◽  
Biljana Stojimirovic
Keyword(s):  
Vitamin D ◽  
Renal Failure ◽  
Peritoneal Dialysis ◽  
End Stage Renal Disease ◽  
Calcium Concentration ◽  
Phosphate Binders ◽  
Active Vitamin ◽  
Active Vitamin D ◽  
Stage Renal Disease ◽  
End Stage

Background/Aim. The disturbances of active forms of vitamin D synthesis and disturbances in calcium and posphate metabolism develop early in chronic renal failure, when creatinine clearance is about 30 ml/min. Chronic hemodialysis and peritoneal dialysis only partially correct the biochemical environment of patients on chronic renal replacement therapy because of end-stage renal disease. These dialysis modalities can?t significantly affect the endocrine disturbances of chronic renal failure and they have minimal modulatory effect. The management of disturbed calcium (Ca) and phosphate (P) metabolism and the maintainance of Ca ? P product below 4.4 mmol/l thanks to the use of dialysate solutions with the appropriate calcium concentration and the careful dosage of phosphate binders, calcium and active vitamin D metabolits, are extremely important for the prevention of renal osteodystrophy, secondary hyperparathyroidism as well as low-bone turnover disease. The aim of the study was to analyze the plasma levels of calcium, phosphate, albumin, alkaline phosphatase and parathormon (PTH) in 58 patients who were treated with continuous ambulatory peritoneal dialysis (CAPD) from March to August 2003. The use of phosphate binders and the substitution with active vitamin D metabolits were also analyzed. Methods. We examined 58 patients, 30 males and 28 female, mean-age 52 years (range, 26-78 years), affected by end-stage renal disease of the different leading cause. The average time on peritoneal dialysis program was 20 months (2-66 months). Most of the patients were treated by CAPD, while only few of them performed automatic, cyclic or intermittent peritoneal dialysis. Most of the patients used a dialysate with 1.75 mmol/l calcium concentration. Results. The study showed that our patients on chronic CAPD program during several months had normal calcemia, phosphatemia and the level of alkaline phosphatase, and that they had Ca ? P product in the recommended range. PTH serum level ranged from 16 to 490 pg/l in our patients. Conclusion. The study showed that a balanced diet and a correct dosage of phosphate binders, as well as a careful substitution with active vitamin D metabolits render a good control of calcium and phosphate serum balance, as well as an effective prevention of renal osteodystrophy development in the patients on chronic peritoneal dialysis treatment.

Sign in / Sign up

Export Citation Format

Share Document